Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Polyneuropathy, Inflammatory Demyelinating, Chronic: later-stage trial registry
2 of 2 indexed Polyneuropathy, Inflammatory Demyelinating, Chronic trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Polyneuropathy, Inflammatory Demyelinating, Chronic: 2 US clinical trials tracked, 2 recruiting.
Polyneuropathy, Inflammatory Demyelinating, Chronic is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 2 of these trials.
Enrollment posture brief
Registry condition polyneuropathy-inflammatory-demyelinating-chronic
OPEN 2 | RECR 100% | LATE 1 | EARLY 0 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Polyneuropathy, Inflammatory Demyelinating, Chronic lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Polyneuropathy, Inflammatory Demyelinating, Chronic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Polyneuropathy, Inflammatory Demyelinating, Chronic is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
Sanofi
NCT06968975
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Sanofi
NCT06290128
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Polyneuropathy, Inflammatory Demyelinating, Chronic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Polyneuropathy, Inflammatory Demyelinating, Chronic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Polyneuropathy, Inflammatory Demyelinating, Chronic page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Polyneuropathy, Inflammatory Demyelinating, Chronic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sanofi sponsors the most Polyneuropathy, Inflammatory Demyelinating, Chronic trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Polyneuropathy, Inflammatory Demyelinating, Chronic condition card totals 2 registered trials; most-linked intervention Riliprubart; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.